JP2023541379A - 神経系の疾患及び障害を改善するための組成物及び方法 - Google Patents

神経系の疾患及び障害を改善するための組成物及び方法 Download PDF

Info

Publication number
JP2023541379A
JP2023541379A JP2023513936A JP2023513936A JP2023541379A JP 2023541379 A JP2023541379 A JP 2023541379A JP 2023513936 A JP2023513936 A JP 2023513936A JP 2023513936 A JP2023513936 A JP 2023513936A JP 2023541379 A JP2023541379 A JP 2023541379A
Authority
JP
Japan
Prior art keywords
agonist
pabra
beta
less
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541379A5 (enExample
Inventor
アンソニー ピー． フォード
ガブリエル バルガス
ウェイ チェン
レネー エス． マーティン
Original Assignee
キュラセン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュラセン セラピューティクス インコーポレイテッド filed Critical キュラセン セラピューティクス インコーポレイテッド
Publication of JP2023541379A publication Critical patent/JP2023541379A/ja
Publication of JP2023541379A5 publication Critical patent/JP2023541379A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/501—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the head, e.g. neuroimaging or craniography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023513936A 2020-09-01 2021-08-31 神経系の疾患及び障害を改善するための組成物及び方法 Pending JP2023541379A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063073353P 2020-09-01 2020-09-01
US63/073,353 2020-09-01
US202163212077P 2021-06-17 2021-06-17
US63/212,077 2021-06-17
PCT/US2021/048540 WO2022051305A1 (en) 2020-09-01 2021-08-31 Compositions and methods for improving neurological diseases and disorders

Publications (2)

Publication Number Publication Date
JP2023541379A true JP2023541379A (ja) 2023-10-02
JP2023541379A5 JP2023541379A5 (enExample) 2024-09-09

Family

ID=80491939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513936A Pending JP2023541379A (ja) 2020-09-01 2021-08-31 神経系の疾患及び障害を改善するための組成物及び方法

Country Status (9)

Country Link
US (1) US20230263749A1 (enExample)
EP (1) EP4208159A4 (enExample)
JP (1) JP2023541379A (enExample)
KR (1) KR20230107211A (enExample)
CN (1) CN116801875B (enExample)
AU (1) AU2021337583A1 (enExample)
CA (1) CA3189243A1 (enExample)
MX (1) MX2023002350A (enExample)
WO (1) WO2022051305A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022185255A1 (en) 2021-03-03 2022-09-09 Lenovo (Singapore) Pte. Ltd. Beam failure detection using multiple sets of reference signals
US20260207568A1 (en) * 2022-12-21 2026-07-23 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
US20250107713A1 (en) * 2023-09-29 2025-04-03 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods for Confirming Iboga Alkaloid Treatment

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51122073A (en) * 1975-04-14 1976-10-25 Smithkline Corp Alphaaaminomethyll55hydoxyy 22pyridinemethanols
JPH01186867A (ja) * 1987-11-27 1989-07-26 Merck & Co Inc 新規なβ−アドレナリン性アゴニスト
US20140235726A1 (en) * 2013-02-13 2014-08-21 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
WO2019241744A1 (en) * 2018-06-14 2019-12-19 Curasen Therapeutics, Inc. Methods for diagnosing, monitoring and treating neurological diseases and disorders
JP2021527711A (ja) * 2018-06-14 2021-10-14 キュラセン セラピューティクス インコーポレイテッド 神経系疾患および障害の改善のための方法
JP2022527769A (ja) * 2019-03-27 2022-06-06 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニスト及びそれを使用する方法
JP2023507408A (ja) * 2019-12-18 2023-02-22 キュラセン セラピューティクス インコーポレイテッド 神経系疾患および障害を改善するための方法
JP2023528450A (ja) * 2020-06-04 2023-07-04 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニストの形態及び組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
WO2002032897A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
WO2018195473A1 (en) * 2017-04-20 2018-10-25 The Brigham And Women's Hospital, Inc. Combinations including beta-adrenoreceptor agonists for treatment of parkinson's disease and movement disorders
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
US20220401415A1 (en) * 2019-10-25 2022-12-22 Curasen Therapeutics, Inc. Methods for treating neurological disorders with alpha1a-ar partial agonists

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51122073A (en) * 1975-04-14 1976-10-25 Smithkline Corp Alphaaaminomethyll55hydoxyy 22pyridinemethanols
JPH01186867A (ja) * 1987-11-27 1989-07-26 Merck & Co Inc 新規なβ−アドレナリン性アゴニスト
US20140235726A1 (en) * 2013-02-13 2014-08-21 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
WO2019241744A1 (en) * 2018-06-14 2019-12-19 Curasen Therapeutics, Inc. Methods for diagnosing, monitoring and treating neurological diseases and disorders
JP2021527712A (ja) * 2018-06-14 2021-10-14 キュラセン セラピューティクス インコーポレイテッド 神経系疾患および障害を、診断、監視、および治療するための方法
JP2021527711A (ja) * 2018-06-14 2021-10-14 キュラセン セラピューティクス インコーポレイテッド 神経系疾患および障害の改善のための方法
JP2022527769A (ja) * 2019-03-27 2022-06-06 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニスト及びそれを使用する方法
JP2023507408A (ja) * 2019-12-18 2023-02-22 キュラセン セラピューティクス インコーポレイテッド 神経系疾患および障害を改善するための方法
JP2023528450A (ja) * 2020-06-04 2023-07-04 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニストの形態及び組成物

Also Published As

Publication number Publication date
AU2021337583A1 (en) 2023-05-04
KR20230107211A (ko) 2023-07-14
EP4208159A1 (en) 2023-07-12
CA3189243A1 (en) 2022-03-10
MX2023002350A (es) 2023-04-26
CN116801875B (zh) 2026-06-05
AU2021337583A9 (en) 2024-06-27
WO2022051305A1 (en) 2022-03-10
CN116801875A (zh) 2023-09-22
US20230263749A1 (en) 2023-08-24
EP4208159A4 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
JP7744344B2 (ja) 神経系疾患および障害を改善するための方法
JP2021527712A (ja) 神経系疾患および障害を、診断、監視、および治療するための方法
US20110236307A1 (en) In vivo imaging method
JP2021527711A (ja) 神経系疾患および障害の改善のための方法
KR20230107211A (ko) 신경학적 질환 및 장애를 개선하기 위한 조성물 및 방법
JP4943159B2 (ja) 新規示差画像形成法
Jia et al. 99mTc (CO) 3-Labeled benzothiazole derivatives preferentially bind cerebrovascular amyloid: potential use as imaging agents for cerebral amyloid angiopathy
CN116251199A (zh) 结合α-突触核蛋白聚集体的小分子探针及其用途
CN106008374B (zh) 吡嗪类化合物及其在医药上的用途
US20250134835A1 (en) Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)
US12616667B2 (en) Compositions and methods for improving neurological diseases and disorders
WO2025188807A1 (en) Combination compositions and methods of use
WO2024137506A1 (en) Compositions and methods for improving neurological diseases and disorders
US20210251923A1 (en) Methods for improving neurological diseases and disorders
WO2024137478A1 (en) Methods for treating various conditions and indications with agonists and antagonists
CN111253398B (zh) 一种用于检测神经损伤的荧光化合物及其应用
WO2023250332A1 (en) Compositions and methods involving isolated compounds
WO2023250334A1 (en) Compositions and methods involving isolated compounds
JP2023103293A (ja) 可溶性エポキシドヒドロラーゼ（ｓＥＨ）のＰＥＴイメージング用１８Ｆ－ＦＮＤＰ

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260727